Breaking News

BioSig Acquires Anti-viral Agent to Treat COVID-19

Laboratory results demonstrate high level of activity against COVID-19 in cell culture

By: Contract Pharma

Contract Pharma Staff

BioSig Technologies, a medical technology company commercializing a proprietary biomedical signal processing platform, announced that its majority-owned subsidiary NeuroClear Technologies, acquired the rights to develop a novel pharmaceutical to treat coronavirus disease 2019 (COVID-19).   In a preliminary internal review, the orally administered, broad-spectrum anti-viral agent Vicromax demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. In this analysis, Vicro...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters